文献速递食管胃疾病与幽门螺杆菌炎症性肠病肝病

胃肠病学中的益生菌:成人证据有多充分?

Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?
PubMed 文献 · Am J Gastroenterol · 2018-06-19

本文综述了成人胃肠疾病中益生菌的随机对照试验,按菌属/菌种整理数据并用GRADE系统评估证据可靠性。多数试验规模小、质量低;粪菌移植治疗复发性艰难梭菌感染证据充分,乳杆菌、双歧杆菌、链球菌或布拉氏酵母菌预防抗生素相关腹泻及作为幽门螺杆菌辅助治疗有中等质量证据,但其他适应证的证据受限,尚不能推荐常规使用。

要点

  • 粪菌移植治疗复发性艰难梭菌感染证据充分。
  • 乳杆菌、双歧杆菌、链球菌或布拉氏酵母菌预防抗生素相关腹泻有中等质量证据。
  • 乳杆菌、双歧杆菌或酵母菌作为幽门螺杆菌辅助治疗有中等质量证据。

核心结论

  • 粪菌移植治疗复发性艰难梭菌感染证据充分;部分益生菌用于预防抗生素相关腹泻和幽门螺杆菌辅助治疗有中等质量证据;其他适应证的证据受限,尚不能推荐常规使用。

研究设计与样本

  • 综述了成人胃肠疾病中已鉴定的随机对照试验,按益生菌菌属/菌种整理数据,并用GRADE系统评估证据可靠性。

主要发现

  • 多数已鉴定的随机对照试验规模小、质量低,结论受方法学问题限制。
  • 粪菌移植治疗复发性艰难梭菌感染证据充分。
  • 乳杆菌、双歧杆菌、链球菌或布拉氏酵母菌预防抗生素相关腹泻有中等质量证据。
  • 乳杆菌、双歧杆菌或酵母菌作为幽门螺杆菌辅助治疗有中等质量证据。
  • 其他有支持证据的情况包括VSL#3维持贮袋炎缓解或治疗活动性溃疡性结肠炎、粪菌移植治疗活动性溃疡性结肠炎、双歧杆菌治疗缓解期溃疡性结肠炎、乳杆菌治疗疼痛性憩室病、多种益生菌治疗轻微肝性脑病、肝移植术后提供合生元。

临床怎么用

  • 作者认为,由于证据的局限性,未来研究很可能影响估计的获益,这些干预措施尚不能推荐常规使用。

局限性

  • 多数已鉴定的随机对照试验规模小、质量低,任何结论至少受方法学问题限制。
  • 证据的其他局限性使未来研究很可能影响估计的获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Probiotic usage has become popular with both medical practitioners and the community in general; patients commonly seek advice regarding what, if any, such preparation would be useful for their own diseases. Since such advice should be evidence-based, identified randomized clinical trials (RCTs) for a number of gastrointestinal conditions were reviewed; the data were organized by individual probiotic genera/species. Only trials in adults were considered. Most of the identified RCTs were small and low-quality, so any conclusions to be drawn will be limited at least by methodologic problems. Using the GRADE system to consider the reliability of the evidence generated from these RCTs, it did appear that the use of fecal microbial transplantation to treat recurrent Clostridium difficile infection is well justified. Given the methodologic issues, there was moderately good evidence for preventing antibiotic-associated diarrhea with Lactobacillus, Bifidobacterium, Streptococcus, or Saccharomyces boulardii and for using Lactobacillus, Bifidobacterium, or Saccharomyces as adjunct therapy in the treatment of Helicobacter pylori. There were other conditions for which some supportive evidence was available. These conditions include VSL#3 for maintaining remissions in patients with pouchitis or treating active ulcerative colitis (UC), fecal microbial transplantation for treating active UC, Bifidobacterium for treating patients with UC in remission, Lactobacillus in patients with painful diverticulosis, a variety of probiotics (Lactobacillus, Bifidobacterium, Streptococcus, or VSL#3) in patients with minimal hepatic encephalopathy, and providing synbiotics to patients postoperatively after liver transplantation. Unfortunately, other limitations in the evidence made it very likely that future research will have an effect on the estimated benefit; these interventions cannot yet be recommended for routine use.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Koretz RL. Probiotics in Gastroenterology: How Pro Is the Evidence in Adults? Am J Gastroenterol. 2018. PMID: 29915396. doi:10.1038/s41395-018-0138-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。